NCT03033108

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Kubota Vision Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.

Detailed description

This is a multicenter, randomized, masked study to characterize the pharmacodynamics, safety and tolerability of emixustat in subjects with macular atrophy secondary to Stargardt disease.

Conditions

• Stargardt Disease
• Macular Atrophy

Interventions

Type	Name	Description
DRUG	Emixustat	Once daily, tablet for oral administration

Timeline

• Start date: 2017-01-01
• Primary completion: 2017-11-01
• Completion: 2017-12-01
• First posted: 2017-01-26
• Last updated: 2021-05-19
• Results posted: 2021-04-27

Locations

1 site across 1 country: United States